Obstructive sleep apnea (OSA) needs to be addressed as a multilevel disease, especially in patients who fail or can’t tolerate continuous positive airway pressure (CPAP).

Although functional endoscopic sinus surgery (FESS) is a commonly used and well-established tool for the treatment of chronic rhinosinusitis, between 10% and 20% of patients will have recurrent disease and require further surgery.

A regimen of six weekly shots of a novel vaccine may be an effective long-term approach for patients with allergic rhinitis, sparing them injections once or twice a week for three to five years, according to results of a pilot study published recently in the New England Journal of Medicine.

There is an increased awareness of sleep-disordered breathing in children, but even after tonsillectomy and adenoidectomy (T&A), between 5% and 10% of all cases have persistent obstructive sleep apnea (OSA).

Even when their cancers are cured or in remission, patients with head and neck cancers face multiple challenges that can impinge on their quality of life (QOL).

Mounting evidence suggests that bacterial biofilms play a role in chronic inflammatory infections of the middle ear and sinuses.

Sleep disorders pervade all levels of our society, affecting people of all ages, races, and socioeconomic levels.

Passed in 1996, the Health Insurance Portability and Accountability Act (HIPAA) -in particular, Title II, Preventing Health Care Fraud and Abuse; Administrative Simplification and Medical Liability-was intended to establish a federal floor of protections for managing the evolving technologies of storing and sharing electronic health information.